Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2021-01-04 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
2020年第四季度可转换公司债券转股情况公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the convertible bonds (可转换公司债券) of 特一药业集团股份有限公司 for the fourth quarter of 2020. It details the bond issuance, conversion price adjustments, and the changes in shareholding due to bond conversions during the quarter. The document includes specific bond codes, conversion prices, regulatory approvals, and shareholding changes. It is not a full financial report like an Annual Report or Interim Report, nor is it a call transcript or management report. It is a regulatory announcement about bond conversion and shareholding changes related to convertible bonds. This fits best under Capital/Financing Update (CAP) as it relates to financing activities and capital structure changes due to convertible bond conversions.
2021-01-04 Chinese
关于全资子公司头孢拉定胶囊药品通过一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a pharmaceutical product (头孢拉定胶囊) by the national drug regulatory authority, specifically about passing a consistency evaluation for generic drug quality and efficacy. It includes details about the drug specifications, approval notice, and the impact on the company. There are no financial statements, earnings data, or management discussion of financial results. The document is an official announcement of a regulatory approval event related to the company's product, not a financial report or meeting material. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-12-09 Chinese
关于非公开发行股票申请获得中国证监会核准批复的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the approval from the China Securities Regulatory Commission (CSRC) for a non-public issuance of shares by the company 特一药业集团股份有限公司. It details the approval, conditions, and contact information related to the issuance. There are no financial statements or detailed financial data presented, nor is this a report or presentation. The document is clearly an update on a capital raising activity (non-public issuance of shares). Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and focused on the announcement of the approval, not a full report or prospectus.
2020-12-07 Chinese
可转换公司债券2020年付息公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the interest payment for a convertible bond issued by the company 特一药业集团股份有限公司. It details the bond code, interest rates, payment dates, tax treatment, and other procedural information related to the bond interest payment for the year 2020. There are no financial statements, management discussion, or detailed financial results presented. The document is primarily an official notice about the bond interest payment schedule and related details, which fits the category of a Capital/Financing Update (CAP) as it relates to the company's financing instruments and their interest payments.
2020-11-29 Chinese
关于变更保荐机构后重新签署募集资金三方及四方监管协议的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 特一药业集团股份有限公司 regarding the change of the sponsoring institution and the re-signing of three-party and four-party supervision agreements related to the management and use of raised funds from a convertible bond issuance. It details the background of the bond issuance, the amount raised, the use of funds, and the terms of the new supervision agreements. There are no financial statements or detailed financial performance data presented. The document is primarily about regulatory compliance and procedural updates concerning fundraising supervision. It is not a full financial report, earnings release, or management discussion. The document length is about 4,886 characters, which is relatively short and focused on an announcement. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to fundraising activities and capital management updates.
2020-11-17 Chinese
关于全资子公司药品蒙脱石散通过一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 特一药业集团股份有限公司 regarding its wholly-owned subsidiary's drug passing a consistency evaluation by the National Medical Products Administration. It includes details about the drug, approval notification, and potential impact on the company. The document is short (1013 characters) and serves as a regulatory announcement about a product approval, not a financial report or detailed management discussion. There is no financial data, no mention of annual or quarterly results, no board changes, no voting results, or other report types. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about product approval and company impact without fitting other specific categories.
2020-11-11 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.